We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Deborah Wexler

Deborah J. Wexler MD, MSc

Associate Professor of Medicine, Harvard Medical School; Associate Clinical Chief of the Diabetes Unit and Clinical Director, Massachusetts General Hospital Diabetes Center, Boston, Massachusetts

Deborah J. Wexler, MD, MSc, is Associate Professor of Medicine at Harvard Medical School, Boston, Massachusetts, the Associate Clinical Chief of the MGH Diabetes Unit, and Clinical Director of the MGH Diabetes Center.

Dr. Wexler’s research focuses on clinical effectiveness in type 2 diabetes. In addition, she served on the American Diabetes Association’s Professional Practice Committee (2014-2016), is on the Editorial Board of Diabetes Care, and is a reviewer for multiple journals.

Dr. Wexler was a co-author of the ADA-EASD Consensus Report on Management of Type 2 Diabetes, 2018 https://care.diabetesjournals.org/content/early/2018/09/27/dci18-0033

Disclosures

Dr. Wexler reports serving on Data Monitoring Committees for trials of oral semaglutide sponsored by Novo Nordisk.

Recent Contributions to PracticeUpdate:

  1. 2020 Top Stories in Diabetes: The DAPA-CKD Trial
  2. Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function
  3. 2019 Top Stories in Diabetes: The CREDENCE Trial
  4. Cannabis Use Is Associated With Increased Risk for Diabetic Ketoacidosis in Adults With Type 1 Diabetes
  5. Even Moderate Weight Loss After Diabetes Diagnosis Improves Long-Term Cardiovascular Risk
  6. Liraglutide, Sitagliptin, and Insulin Glargine Added to Metformin in Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease
  7. ADA Scientific Sessions 2019: Recommendations From Dr. Deborah Wexler
  8. Morbidity and Mortality After Lifestyle Intervention for People With Impaired Glucose Tolerance
  9. 2018 Top Stories in Diabetes: Canagliflozin and Renal Outcomes in Type 2 Diabetes
  10. Levels of Adherence Needed to Achieve Significant Weight Loss

Most Read This Week

Recently Updated